Equities

Nektar Therapeutics

Nektar Therapeutics

Actions
  • Price (EUR)30.04
  • Today's Change0.68 / 2.32%
  • Shares traded0.00
  • 1 Year change-56.85%
  • Beta2.8550
Data delayed at least 15 minutes, as of May 24 2019 17:42 BST.
More ▼

Profile data is unavailable for this security.

About the company

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

  • Revenue in USD (TTM)1.18bn
  • Net income in USD658.64m
  • Incorporated1998
  • Employees618.00
  • Location
    Nektar Therapeutics455 Mission Bay Blvd SSAN FRANCISCO 94158-2158United StatesUSA
  • Phone+1 (415) 482-5300
  • Fax+1 (302) 655-5049
  • Websitehttp://www.nektar.com
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.